Pamela N. Münster - Concepedia

Author

Pamela N. Münster

University of California, San Francisco ORCID

Also Known As

Bergsland, Emily, Erminia Massarelli, Juric, Dejan, Mendelson, David, Munster P, P MUNSTER, P Munster, P Münster, P N Munster, P N Münster

726

Publications

19.4K

Citations

H-Index

138

Concepts

All Affiliations

University of California, San Francisco Moffitt Cancer Center UCSF Helen Diller Family Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute

About

Pamela N. Münster is an author at University of California, San Francisco specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	82	4.6K
2	Health Sciences	10	12	723
3	Engineering	4	4	129
4	Natural Sciences	4	4	159
5	Nursing	4	4	222

Pamela N. Münster

171

Publications

17.4K

Citations

H-Index

Page 1

	Year	Citations
KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors David S. Hong, Marwan Fakih, John H. Strickler, New England Journal of Medicine	2020	1.6K
Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1- <sup>13</sup> C]Pyruvate Sarah J. Nelson, John Kurhanewicz, Daniel B. Vigneron, Science Translational Medicine	2013	1.2K
Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma Adil Daud, Ronald C. DeConti, Stephanie Andrews, Journal of Clinical Oncology	2008	680
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC Paul C. Tumeh, Matthew D. Hellmann, Omid Hamid, Cancer Immunology Research	2017	543
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal, JAMA Oncology	2019	533
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. David B. Solit, Fuzhong F. Zheng, Marija Drobnjak, PubMed	2002	435
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor Denise A. Yardley, Roohi Ismail‐Khan, Bohuslav Melichar, Journal of Clinical Oncology	2013	410
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer Pamela N. Münster, Kenneth T. Thurn, Scott Thomas, British Journal of Cancer	2011	386
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Pamela N. Münster, Tiffany A. Troso-Sandoval, Neal Rosen, PubMed Histone ModificationsChemoprevention StrategyEpigenetic ChangeCell CycleCancer Biology	2001	373
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer Helen Lee, Anthony F. Shields, Barry A. Siegel, Clinical Cancer Research	2017	359

Page 1